Primary Sclerosing Cholangitis

Table of Contents

1. Overview
2. Epidemiology and IBD Association
3. Pathophysiology
4. Clinical Presentation
5. Diagnosis — MRCP, ERCP, and Biopsy
6. Differential Diagnosis — PSC vs PBC vs IgG4-SC
7. Cancer Surveillance
8. Treatment and Management
9. Liver Transplantation
10. Prognosis
11. References
12. Featured Videos

Overview

Primary Sclerosing Cholangitis (PSC) is a progressive fibro-obliterative disease of the bile ducts that affects both intrahepatic and extrahepatic bile ducts. The hallmark is a characteristic "onion skin" concentric fibrosis surrounding bile ducts, which leads to progressive biliary strictures, cholestasis, biliary cirrhosis, and ultimately liver failure. PSC is a chronic and relentlessly progressive disease for which no approved medical therapy has been proven to alter the natural history.

PSC is clinically and mechanistically distinct from Primary Biliary Cholangitis (PBC) in several critical ways. PSC predominantly involves large bile ducts visible on cholangiography, whereas PBC is an autoimmune attack on small intrahepatic bile ducts. PSC carries a strong association with inflammatory bowel disease (IBD) — present in 70–80% of patients — a link not seen with PBC. PSC has a male predominance (2:1 M:F), in sharp contrast to PBC's overwhelming female predominance (9:1 F:M). The anti-mitochondrial antibody (AMA) that is pathognomonic for PBC is absent in PSC. Most patients are diagnosed between ages 30 and 40.

The diagnosis of PSC rests on cholangiographic demonstration of multifocal bile duct strictures and dilatations — the classic "beaded" appearance — most commonly obtained by Magnetic Resonance Cholangiopancreatography (MRCP). The primary clinical concern beyond progressive liver failure is the dramatically elevated lifetime risk of cholangiocarcinoma (10–15%), requiring vigilant annual cancer surveillance. The only curative treatment remains liver transplantation, which offers excellent 5-year survival rates of 80–85%.

Back to Table of Contents

Epidemiology and IBD Association

PSC is a relatively rare disease in the general population, with an annual incidence of approximately 1 per 100,000 and a prevalence of roughly 10 per 100,000 in Western countries. Despite its rarity, PSC has an outsized clinical significance due to its association with IBD, its malignant potential, and its position as a leading indication for liver transplantation in young adults.

Sex and Age: PSC demonstrates a male predominance of approximately 2:1, which stands in stark contrast to most other autoimmune liver diseases. The median age at diagnosis is between 30 and 40 years, making PSC a disease that affects adults in their most productive years. However, PSC can present at any age, including in children and elderly adults.

The IBD Connection: The relationship between PSC and IBD is one of the most striking disease associations in hepatology. Approximately 70–80% of PSC patients have concurrent IBD, most commonly ulcerative colitis (UC) accounting for 70–80% of PSC-associated IBD cases. Crohn's colitis accounts for another 10–15%, while isolated small-bowel Crohn's disease is rarely associated with PSC.

The IBD in PSC has a distinctive phenotype: it is typically a pancolitis (affecting the entire colon) but is often clinically mild or quiescent — sometimes described as "one of nature's experiments." A paradoxical inverse relationship is frequently observed where IBD activity is mild precisely when PSC is severe, and vice versa. Many PSC patients are surprised to learn they have colitis at all, as their bowel symptoms may be minimal or absent despite widespread mucosal involvement.

The inverse side of this relationship is equally important: only 2–8% of patients with UC or IBD will develop PSC. PSC is therefore not simply a complication of IBD in general — it appears to arise in a genetically and immunologically distinct subset of IBD patients.

Genetic Risk Factors: PSC has a strong genetic predisposition. HLA associations include HLA-B8, HLA-DR3, and HLA-DR2 — the same HLA haplotypes associated with other autoimmune conditions. Genome-wide association studies (GWAS) have identified multiple additional risk loci, particularly in immune pathway genes, suggesting that dysregulated immune responses are central to PSC pathogenesis even though it is not classically categorized as a traditional autoimmune disease.

Back to Table of Contents

Pathophysiology

The fundamental mechanisms driving PSC remain poorly understood, which explains the lack of effective disease-modifying therapy. Several non-mutually exclusive hypotheses have been proposed, each supported by different lines of evidence.

1. The Gut-Liver Axis (Dysbiosis Hypothesis): The most compelling hypothesis centers on the unique co-occurrence of PSC and IBD. In IBD, a disrupted intestinal barrier ("leaky gut") allows gut bacteria, microbial products, and activated immune cells to translocate into the portal circulation. This repeated exposure of the biliary epithelium to pathogenic stimuli triggers an aberrant immune response and subsequent fibrosis. Crucially, gut-homing lymphocytes (expressing CCR9 and α4β7 integrins that normally direct them to the intestinal mucosa) are found in the liver parenchyma of PSC patients, suggesting that misdirected gut immune trafficking is central to biliary injury. The gut-liver axis hypothesis is uniquely supported in PSC by its tight IBD association, which is not seen in other cholangiopathies such as PBC.

2. Molecular Mimicry: Gut microbiome antigens may share structural similarities with biliary epithelial cell antigens. Exposure of the immune system to these microbial antigens (particularly in the context of a leaky gut) could trigger cross-reactive immune responses targeting bile duct epithelial cells, leading to periductal inflammation and subsequent fibrosis. This hypothesis blends gut-liver axis dysfunction with antigen-driven autoimmunity.

3. Genetic Immune Dysregulation: GWAS studies have identified over 20 risk loci associated with PSC, with enrichment in genes involved in T-cell activation, cytokine signaling, and NF-κB pathways. HLA-B8 and HLA-DR3 are strongly associated, suggesting that antigen presentation and T-cell activation are critical. However, unlike PBC — where specific AMA antibodies clearly point to an autoimmune etiology — PSC lacks a specific pathogenic autoantibody, suggesting the mechanism may be more T-cell-mediated than B-cell-mediated.

4. Periductal Fibrosis — The Histological Hallmark: Regardless of the initiating trigger, the downstream result is activation of hepatic stellate cells and portal myofibroblasts, leading to concentric periductal fibrosis around interlobular bile ducts — the characteristic "onion skin" fibrosis on liver biopsy. This progressive fibrosis obliterates bile duct lumens, creating strictures. The resulting cholestasis and biliary stasis promote secondary bacterial colonization, recurrent cholangitis, and ultimately biliary cirrhosis.

Comparison with PBC: Understanding PSC pathophysiology is sharpened by contrast with PBC. PBC is a well-characterized autoimmune disease driven by AMA targeting the E2 subunit of pyruvate dehydrogenase complex on small intrahepatic bile duct epithelial cells. PBC responds to UDCA and obeticholic acid. PSC, by contrast, is a fibro-obliterative disease of large and small bile ducts with an unknown trigger, no specific pathogenic antibody, no proven response to immunosuppressants or bile acid therapy, and a gut-linked pathogenesis that distinguishes it from virtually all other liver diseases.

Back to Table of Contents

Clinical Presentation

The clinical presentation of PSC is highly variable. A substantial proportion of patients — particularly those diagnosed in the era of routine liver chemistry testing — are asymptomatic at diagnosis, with PSC discovered incidentally through abnormal liver function tests during IBD follow-up or routine health screening. The most common biochemical pattern is a cholestatic liver profile: disproportionate elevation of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), with lesser increases in aminotransferases (AST, ALT) and bilirubin early in the course.

The index of suspicion rule: Any IBD patient — especially one with UC — who develops an elevated ALP or GGT warrants PSC work-up with MRCP. This single clinical rule detects PSC early in a high-risk population before symptoms develop.

Symptomatic Disease: When symptoms are present, they typically include:

• Fatigue: The most common non-specific symptom, present in the majority of symptomatic patients. Like PBC, PSC-associated fatigue is often debilitating and does not correlate well with biochemical or histological disease severity.
• Pruritus: Cholestasis-induced pruritus from bile acid accumulation in the skin. Typically less severe than in PBC but can be significant. The mechanism involves central opioid pathways and possibly lysophosphatidic acid accumulation.
• Jaundice: Progressive jaundice reflects advancing biliary obstruction. Episodic sudden worsening of jaundice suggests the development of a dominant stricture or, more ominously, cholangiocarcinoma.
• Recurrent Bacterial Cholangitis: One of the most distinctive and dangerous complications of PSC. Bacterial superinfection of obstructed bile ducts produces the classic Charcot's Triad: right upper quadrant pain, fever and rigors, and jaundice. Severe episodes may progress to Reynold's Pentad (adding septic shock and altered mental status). Recurrent cholangitis episodes accelerate liver injury and are a major source of morbidity.
• Steatorrhea and Fat-Soluble Vitamin Deficiency: Severe cholestasis reduces bile acid delivery to the duodenum, impairing fat and fat-soluble vitamin absorption (vitamins A, D, E, K). Osteoporosis secondary to vitamin D deficiency is common in advanced PSC.

Dominant Strictures: Approximately 15–20% of PSC patients develop a dominant stricture — a localized area of significant narrowing at the common bile duct or the biliary confluence that causes a disproportionate degree of cholestasis beyond that explained by the underlying diffuse disease. Dominant strictures may be benign (inflammatory fibrous stricture) or malignant (cholangiocarcinoma). The clinical presentation of a dominant stricture — sudden-onset worsening jaundice, cholangitis, or deterioration in liver tests — demands urgent ERCP evaluation with biliary sampling before any dilation is attempted, to exclude underlying cholangiocarcinoma.

End-Stage Disease: Progressive disease leads to biliary cirrhosis with all its complications: portal hypertension, esophageal varices, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and hepatorenal syndrome. The timeline from diagnosis to end-stage liver disease is highly variable, ranging from less than 5 years in rapidly progressive cases to more than 20 years in slowly progressive forms.

Back to Table of Contents

Diagnosis — MRCP, ERCP, and Biopsy

The diagnosis of PSC rests on demonstrating characteristic bile duct abnormalities in the appropriate clinical context. The diagnostic approach has evolved significantly with improved imaging technology.

MRCP (Magnetic Resonance Cholangiopancreatography) — Primary Diagnostic Tool: MRCP has replaced ERCP as the initial diagnostic modality of choice for PSC. MRCP is non-invasive, does not require contrast injection into the bile ducts, and carries no procedural risk. The characteristic PSC finding on MRCP is multifocal strictures and dilatations of the intrahepatic and/or extrahepatic bile ducts, creating the classic "beaded appearance" on cholangiography. Both intrahepatic and extrahepatic duct involvement is typical of large-duct PSC, though intrahepatic duct changes alone may be the presenting finding. In the right clinical context (IBD patient with cholestatic liver biochemistry), a classic beaded MRCP is diagnostic of PSC without the need for liver biopsy or ERCP.

MRCP limitations include lower sensitivity than ERCP for subtle early-stage changes, and inability to perform simultaneous therapeutic interventions. Gadolinium-enhanced MRCP with 3D reconstructions has improved diagnostic accuracy.

ERCP (Endoscopic Retrograde Cholangiopancreatography) — Interventional Role: ERCP is no longer used for the initial diagnosis of PSC when MRCP is diagnostic. ERCP is reserved for therapeutic interventions:

• Evaluation and management of dominant strictures — balloon dilation with or without short-term stenting
• Biliary sampling for cancer surveillance — brush cytology, FISH (fluorescence in situ hybridization) for chromosomal polysomy, and SpyGlass cholangioscopy with directed biopsy for indeterminate strictures
• Bile culture for recurrent bacterial cholangitis to guide antibiotic therapy

ERCP in PSC carries higher procedural risks than in non-PSC patients, including post-procedural cholangitis, pancreatitis, and bacteremia. Short-term stenting is preferred over long-term stents, which increase infection risk in the setting of biliary strictures.

Liver Biopsy: Liver biopsy is not required for diagnosis when MRCP is classic in a PSC-IBD patient. However, biopsy is valuable in specific circumstances:

• Staging of fibrosis when clinical staging is uncertain
• Small-duct PSC diagnosis — where cholangiography is normal but biopsy shows periductal "onion skin" fibrosis (see below)
• Overlap syndrome evaluation — when features of autoimmune hepatitis co-exist (PSC-AIH overlap)
• Assessment of disease activity in clinically ambiguous cases

The histological hallmark is concentric periductal "onion skin" fibrosis around interlobular bile ducts, with eventual obliteration of the duct lumen and replacement by fibrous tissue — "fibro-obliterative cholangiopathy."

Small-Duct PSC: Approximately 5–10% of PSC patients have small-duct PSC — a variant characterized by normal cholangiography (MRCP and ERCP) but classic PSC histology on liver biopsy. Small-duct PSC carries a significantly better prognosis than large-duct PSC, with slower progression and lower CCA risk. Approximately 20% of small-duct PSC cases will progress to large-duct PSC over time, at which point the prognosis mirrors classical PSC.

Serum IgG4 — Mandatory Exclusion Test: Serum IgG4 must be measured in every patient suspected of having PSC. IgG4-related sclerosing cholangitis (IgG4-SC) mimics PSC radiographically — including the beaded cholangiogram — but is a completely different disease that responds dramatically to corticosteroid therapy. An IgG4 level greater than 4× the upper limit of normal (ULN), combined with cholangiographic findings and other IgG4-related disease features, strongly suggests IgG4-SC. Missing IgG4-SC and treating the patient as PSC denies them the benefit of steroid therapy, which can achieve complete or near-complete resolution. ANA and ASMA should also be checked to evaluate for PSC-AIH overlap syndrome.

Back to Table of Contents

Differential Diagnosis — PSC vs PBC vs IgG4-SC

Distinguishing PSC from other cholestatic liver diseases is critical because the diagnosis dictates treatment. The three most important conditions in the differential diagnosis are Primary Biliary Cholangitis (PBC), IgG4-related Sclerosing Cholangitis (IgG4-SC), and Secondary Sclerosing Cholangitis (from biliary stones, surgery, or ischemia).

Secondary Sclerosing Cholangitis must also be excluded — this term applies to bile duct changes identical to PSC but caused by an identifiable secondary cause: choledocholithiasis (bile duct stones), post-surgical biliary strictures, recurrent pyogenic cholangitis, ischemic cholangiopathy (particularly after liver transplantation), AIDS cholangiopathy, or prior hepatic artery infusion chemotherapy. The diagnosis of PSC requires exclusion of these secondary causes.

Back to Table of Contents

Cancer Surveillance

Cancer surveillance is one of the most critical aspects of PSC management. PSC carries substantially elevated risks for three distinct malignancies: cholangiocarcinoma, gallbladder cancer, and colorectal cancer (in PSC+IBD patients).

Cholangiocarcinoma (CCA) — The Primary Concern: CCA is the most feared complication of PSC. PSC patients face a lifetime CCA risk of 10–15% — a risk that is approximately 400 times higher than in the general population. CCA typically arises in the setting of longstanding biliary inflammation and fibrosis, though it can occur at any disease stage, including at the time of PSC diagnosis. PSC-associated CCA carries a dismal prognosis when unresectable, which accounts for the majority of cases at diagnosis.

Annual surveillance for CCA is recommended:

• MRCP (annually): to detect new or changing biliary strictures, masses, or duct dilatations suggesting CCA development
• Serum CA 19-9 (annually): a tumor marker with moderate sensitivity for CCA in the PSC context; most useful when rising serially rather than as a single elevated value
• Neither MRCP nor CA 19-9 is sufficiently sensitive or specific alone — combined use improves detection

Dominant Strictures and CCA Differentiation: The most challenging diagnostic problem in PSC surveillance is determining whether a dominant stricture is benign (fibro-inflammatory) or malignant. This requires ERCP-based evaluation:

• Brush cytology: sensitivity for CCA approximately 30–40%; specificity high when positive
• FISH (Fluorescence In Situ Hybridization) for chromosomal polysomy: detects chromosomal amplification in malignant biliary cells; sensitivity ~50–60%, specificity >90%; polysomy on FISH carries high specificity for malignancy
• SpyGlass cholangioscopy with directed forceps biopsy: newest modality; allows direct visualization of biliary mucosa and targeted biopsy of suspicious areas
• Combination of cytology + FISH + cholangioscopy achieves the highest diagnostic accuracy for indeterminate dominant strictures

Gallbladder Cancer — Elevated Risk: PSC is associated with an elevated risk of gallbladder adenocarcinoma, not just gallbladder polyps. Annual abdominal ultrasound for gallbladder evaluation is recommended for all PSC patients. The critical distinction from general population management: in PSC, cholecystectomy is recommended for any gallbladder polyp, regardless of size. In the general population, polyps smaller than 1 cm are typically observed — this conservative approach is not appropriate for PSC patients given the heightened malignant potential.

Colorectal Cancer (CRC) in PSC+IBD: PSC+IBD confers a substantially elevated CRC risk. PSC+UC patients have a 4–5 fold higher CRC risk than UC patients without PSC, even after adjusting for UC severity and extent. The mechanism may involve alterations in secondary bile acid metabolism affecting colonic mucosal exposure. As a result:

• Annual colonoscopy with chromoendoscopy or random 4-quadrant biopsies is recommended for all PSC+IBD patients from the time of PSC diagnosis — regardless of IBD activity or severity
• This is a more aggressive interval than the 1–2 year colonoscopy surveillance recommended for UC alone
• The elevated CRC risk persists after liver transplantation and may even increase in some patients as altered immunosuppression affects mucosal immune surveillance; annual colonoscopy must therefore continue post-transplant

Hepatocellular Carcinoma (HCC): Once PSC has progressed to cirrhosis, HCC risk rises as with any cirrhotic liver. Standard HCC surveillance — liver ultrasound with or without AFP every 6 months — is recommended once cirrhosis is established.

Back to Table of Contents

Treatment and Management

Management of PSC is one of the most challenging problems in hepatology because no medical therapy has been proven to alter the natural history of PSC. This stands in stark contrast to PBC, where UDCA (ursodeoxycholic acid) significantly improves transplant-free survival. The search for effective PSC therapy has been ongoing for decades with multiple failures.

UDCA — Controversial and Not Standard of Care: UDCA (ursodeoxycholic acid) reliably improves liver biochemistry in PSC — ALP, GGT, and bilirubin all typically fall with UDCA therapy. However, biochemical improvement has not translated into improved outcomes in clinical trials.

The pivotal landmark trial establishing UDCA's limits in PSC was the 2009 Mayo Clinic RCT by Lindor et al. (Hepatology 2009; PMID: 19585548): high-dose UDCA at 28–30 mg/kg/day was associated with significantly increased risk of death, liver transplantation, and cholangiocarcinoma compared to placebo. This trial definitively established that high-dose UDCA is contraindicated in PSC. Low-dose UDCA (13–15 mg/kg/day) does not carry this harm signal but also has no proven survival benefit. Current clinical practice varies: some hepatologists prescribe low-dose UDCA for biochemical improvement; major guidelines (EASL, AASLD) do not recommend UDCA as standard therapy for PSC given the absence of proven benefit.

Endoscopic Management of Dominant Strictures: While no medical therapy alters PSC course, endoscopic therapy provides meaningful palliation for dominant strictures and biliary complications:

• ERCP with balloon dilation of dominant strictures: improves bile flow, reduces jaundice, and decreases cholangitis episodes; represents the primary endoscopic intervention
• Short-term biliary stenting (7–10 French, weeks to months): used selectively to maintain patency after dilation; long-term stents are avoided due to increased infection risk in the chronically diseased biliary tree
• Cholangioscopy with biopsy for indeterminate strictures before any dilation (CCA exclusion first)
• Endoscopic therapy does not alter long-term disease progression but provides important symptomatic relief and may delay transplantation

Antibiotic Therapy:

• Acute bacterial cholangitis: Ciprofloxacin is the drug of choice due to its excellent biliary penetration and broad-spectrum activity against gram-negative biliary pathogens (Enterobacteriaceae). Piperacillin-tazobactam or carbapenems for severe/complicated cases
• Prophylactic antibiotics for patients with recurrent bacterial cholangitis: ciprofloxacin or trimethoprim-sulfamethoxazole on a rotational schedule; evidence base is limited but clinically practiced
• Gut microbiome modulation: emerging interest in vancomycin (poorly absorbed, acts locally in the colon) to alter gut microbiome composition and potentially the gut-liver axis; early trials show promise in children with PSC; adult trials ongoing

Management of Cholestatic Symptoms:

• Pruritus: cholestyramine (first-line; binds bile acids in the gut); rifampin (second-line; hepatic enzyme induction; monitor LFTs); naltrexone (opioid antagonist; evidence for cholestatic pruritus); sertraline (modest evidence); MARS (molecular adsorbent recirculating system) for refractory intractable pruritus as bridge to transplant
• Fat-soluble vitamin supplementation: vitamins A, D, E, K monitoring and supplementation in cholestatic patients; vitamin D deficiency is particularly common and linked to osteoporosis
• Bone health: DEXA scan at diagnosis and every 2–3 years; bisphosphonates for established osteoporosis
• Nutrition: medium-chain triglycerides (MCT) for steatorrhea; fat-soluble vitamin supplementation; zinc supplementation if deficient

Emerging and Investigational Therapies:

NorUrsodeoxycholic Acid (NorUDCA) represents the most promising investigational agent for PSC. NorUDCA is a 24-carbon bile acid — structurally distinct from UDCA by a single carbon deletion in the side chain. This structural difference fundamentally changes its pharmacokinetics: unlike UDCA, NorUDCA undergoes cholehepatic shunting (absorption by cholangiocytes → secreted into bile → reabsorbed by downstream hepatocytes), cycling through the biliary tree without concentrating in bile. This property confers anti-inflammatory and anti-fibrotic effects on biliary epithelium without the bile acid toxicity associated with high-dose UDCA.

The Phase 2 dose-finding trial (Halilbasic et al., J Hepatol 2019; PMID: 30902613) demonstrated dose-dependent significant reductions in ALP. The pivotal Phase 3 NorUDCA-SC-3 trial (Trauner et al., NEJM 2024; PMID: 38739068) reported positive results: NorUDCA 1500 mg/day produced a statistically significant reduction in ALP versus placebo, with a favorable safety profile. If approved, NorUDCA would be the first pharmacological therapy with proven efficacy in PSC, though whether ALP improvement translates to survival benefit remains to be demonstrated in long-term trials.

Other pipeline agents include: FXR agonists (obeticholic acid — studied but benefit in PSC less clear than in PBC); PPAR agonists (fenofibrate); integrin inhibitors targeting gut lymphocyte trafficking; anti-fibrotic agents (IL-13 pathway inhibitors); and fecal microbiome transplantation (FMT) trials targeting the gut-liver axis.

Back to Table of Contents

Liver Transplantation

Liver transplantation remains the only curative treatment for PSC. PSC is among the most common indications for liver transplantation in young adults in Western countries. The outcomes after transplantation for PSC are excellent — among the best of any transplant indication — with 5-year survival rates of 80–85%.

Indications for Transplantation:

• End-stage liver disease (elevated MELD score, varices, ascites, encephalopathy)
• Intractable recurrent bacterial cholangitis despite maximal endoscopic and antibiotic management
• Intractable pruritus refractory to all medical measures
• Selected early cholangiocarcinoma cases (Mayo PSC-CCA protocol; see below)
• Severely impaired quality of life despite compensated liver disease

MELD Score and PSC Caveats: The Model for End-Stage Liver Disease (MELD) score, which determines transplant priority, may both underestimate and overestimate PSC disease severity at different time points. Episodes of dominant stricture cause acute bilirubin elevation that spikes the MELD score, creating perceived urgency that may not reflect true long-term mortality risk. Conversely, patients with recurrent cholangitis and significantly impaired quality of life may have a relatively preserved MELD score. UNOS exception points may be available for PSC patients with recurrent cholangitis or other PSC-specific complications not captured by MELD.

PSC-Cholangiocarcinoma Transplantation — The Mayo Protocol: In most cancer diagnoses, the detection of cholangiocarcinoma eliminates liver transplantation as a treatment option — transplanting a patient with known cancer under conventional immunosuppression typically results in rapid tumor recurrence. PSC-associated hilar CCA (Klatskin tumor) is the remarkable exception where a specialized protocol achieves excellent outcomes. The Mayo Clinic PSC-CCA protocol — a neoadjuvant chemoradiation approach — consists of:

1. Neoadjuvant external beam radiation therapy + intravenous 5-fluorouracil (5-FU) sensitization
2. Brachytherapy (intraluminal radiation via ERCP)
3. Maintenance oral capecitabine until transplant
4. Mandatory staging laparotomy to exclude extrahepatic tumor spread (disqualifier if positive lymph nodes or peritoneal metastases)
5. Liver transplantation for patients who complete neoadjuvant therapy and staging

This protocol achieves approximately 70% 5-year recurrence-free survival in appropriately selected patients with unresectable perihilar CCA — a remarkable outcome for what is otherwise a near-universally fatal malignancy. Patient selection (CCA confirmed or highly suspected, confined to the bile duct, no vascular invasion, no metastases) is critical to program success.

PSC Recurrence After Transplantation: PSC can recur in the transplanted liver. Recurrence rates of 20–30% at 10 years post-transplant have been reported across large series. Recurrent PSC manifests as progressive biliary stricturing on cholangiogram and is a significant cause of graft loss over time, sometimes requiring retransplantation. Risk factors for recurrence are debated but may include donor characteristics, IBD activity, and immunosuppression regimens.

IBD Management Post-Transplant: Liver transplantation does not cure the colon. PSC patients with concurrent IBD face unique challenges post-transplant. IBD may paradoxically flare after liver transplantation — possibly because calcineurin inhibitors (tacrolimus, cyclosporine), which form the backbone of transplant immunosuppression, have less anti-inflammatory activity on colonic mucosa compared to the broader immunomodulation of pre-transplant portal hypertension-related factors. Close coordination between hepatology and gastroenterology is essential. Annual colonoscopy for CRC surveillance must continue indefinitely after transplantation — the elevated colorectal cancer risk in PSC+IBD persists and may actually increase post-transplant.

Back to Table of Contents

Prognosis

PSC is a progressive disease, but its course is highly variable. Some patients remain asymptomatic with stable liver disease for decades, while others experience rapid progression to cirrhosis and liver failure. Predicting individual patient course is challenging.

Natural History Without Transplantation: The median time from PSC diagnosis to death or liver transplantation in the pre-transplant era was reported as approximately 10–20 years in population-based studies. However, this figure is significantly influenced by whether patients were symptomatic at diagnosis:

• Asymptomatic patients with incidentally discovered PSC may have decades of stable disease before symptomatic progression
• Symptomatic patients — particularly those with elevated bilirubin, dominant strictures, and recurrent cholangitis — have a median survival of approximately 6–7 years without transplantation
• CCA development dramatically worsens prognosis at any stage

Small-Duct PSC: The variant with normal cholangiography but classic PSC histology carries a significantly better prognosis, often remaining stable without progression to cirrhosis for many years. Approximately 20% of small-duct PSC patients will progress to large-duct PSC over time, at which point prognosis mirrors classic PSC.

Mayo PSC Risk Score: The validated Mayo PSC Risk Score incorporates five prognostic variables: age, serum bilirubin, AST (aspartate aminotransferase), ALP (alkaline phosphatase), and the presence of esophageal varices. The score generates a predicted survival probability at 1, 2, and 4 years, and is widely used in clinical practice to communicate prognosis and time transplant listing decisions. The score reflects the multifactorial nature of PSC prognosis — biochemical severity, portal hypertension, and patient age all contribute independently.

Factors Independently Associated with Worse Prognosis:

• Elevated serum bilirubin (reflects progressive biliary obstruction)
• Dominant stricture development (risk of CCA; recurrent cholangitis)
• Rising CA 19-9 (CCA surveillance signal)
• Recurrent bacterial cholangitis (accelerates liver injury)
• Advanced histological fibrosis on biopsy
• Older age at diagnosis
• Development of cholangiocarcinoma (overwhelmingly the leading cause of PSC-related death outside transplant centers)

Post-Transplant Prognosis: Liver transplantation dramatically improves prognosis. 5-year survival post-transplant for PSC is 80–85%, among the best outcomes for any chronic liver disease indication. Long-term survival can be affected by PSC recurrence (20–30% at 10 years), de novo IBD activity, and the elevated colorectal cancer risk that persists post-transplant. Regular follow-up in a specialized transplant hepatology center with integrated gastroenterology for IBD/CRC surveillance is essential for optimal long-term outcomes.

Back to Table of Contents

References

1. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808–814. PMID: 19585548
2. Trauner M, Halilbasic E, Hautekeete M, et al. NorUrsodeoxycholic Acid for Primary Sclerosing Cholangitis: Phase 3 Trial (NorUDCA-SC-3). N Engl J Med. 2024. PMID: 38739068
3. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis — a comprehensive review. J Hepatol. 2017;67(6):1298–1323. PMID: 28802875
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–267. PMID: 19501929
5. Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017;152(8):1975–1984.e8. PMID: 28254599
6. Lazaridis KN, LaRusso NF. Primary Sclerosing Cholangitis. N Engl J Med. 2016;375(12):1161–1170. PMID: 27653566
7. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002;37(10):1205–1211. PMID: 12408526; see also: Boberg KM, et al. Hepatology. 2002;36(3):523–528. PMID: 12198640
8. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321–327. PMID: 11867176
9. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 1991;213(1):21–25. PMID: 1845927; Mayo Clinic experience: Rosen CB, et al. J Hepatol. 1991;13(3):367–370. PMID: 1761983
10. Folseraas T, Melum E, Franke A, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol. 2012;57(2):366–375. PMID: 22521341
11. Björnsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007;45(6):1547–1554. PMID: 17538977; see also: Björnsson E, et al. Gastroenterology. 2007;133(4):1113–1122. PMID: 17919488
12. Halilbasic E, Fiorotto R, Fickert P, et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice. Hepatology. 2009;49(6):1972–1981; Phase 2 dose-finding study: Halilbasic E, et al. J Hepatol. 2019;70(6):1095–1102. PMID: 30902613

Back to Table of Contents

Connections

• Primary Biliary Cholangitis (PBC)
• Cirrhosis
• Liver Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis
• Autoimmune Hepatitis
• Budd-Chiari Syndrome
• Nephrology & Hepatology
• All Conditions

Back to Table of Contents

Featured Videos